Events And Losses That Shook India Pharma In The Decade
Executive Summary
The past decade witnessed a bout of pharma 'shock and awe' events in India, some of which still reverberate across the industry. The period also marked the death of doyens of the Indian pharmaceutical sector, including the founders of Dr Reddy’s and Lupin.
You may also be interested in...
Natco Settles Over Canadian Revlimid Rival
India’s Natco has struck a deal with Celgene to settle litigation over its proposed generic lenalidomide rival to Revlimid in Canada. News of the settlement came shortly after the Indian firm reported a decline in quarterly and annual revenues following supply chain disruptions caused by the coronavirus crisis.
Decade In Review: C-Suite Shifts At Family-Owned Indian Firms
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
India 2019 – R&D Highs, Compliance Woes And Other Lows
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.